The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•15 March 2026•

1 min read

Telix Resubmits FDA Application for Pixclara Brain Cancer Imaging Agent

Key Facts

1Telix Pharmaceuticals resubmitted a New Drug Application (NDA) to the U.S. FDA for TLX101-Px (Pixclara).

2The product is a PET imaging agent for characterizing recurrent or progressive glioma (brain cancer) in adult and pediatric patients.

Telix Pharmaceuticals has officially resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Pixclara (TLX101-Px). The investigational product is designed as a PET imaging agent specifically for characterizing recurrent or progressive glioma in both adult and pediatric patients. A key clinical benefit of Pixclara is its ability to help clinicians distinguish between actual tumor progression and changes caused by prior treatments. This resubmission represents a critical regulatory milestone for the company as it seeks marketing authorization in the United States. If approved, the diagnostic tool could provide a significant advancement in the management of brain cancer patients. Investors view this progress as a positive catalyst, moving the company closer to potential commercialization and revenue generation.